Zota Health Care releases Q4FY26 earnings call audio
Zota Health Care Limited released the audio recording of its earnings conference call for Q4 and FY26 held on May 25, 2026. The call covered operational and financial performance, and the recording is available on the company's website under SEBI Regulation 30(6).

*this image is generated using AI for illustrative purposes only.
Zota Health Care Limited has made available the audio recording of its earnings conference call regarding the financial results for the fourth quarter and year ended March 31, 2026. The call was hosted on May 25, 2026, to review the company's operational and financial performance during the specified periods. Investors can access the recording through the official website of the company.
The disclosure was made in compliance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to The National Stock Exchange of India Limited to inform the exchange and its stakeholders about the availability of this information.
Ashvin Variya, Company Secretary & Compliance Officer of Zota Health Care Limited, signed the disclosure. The registered office of the company is located at Zota House, 2/896, Hira Modi Street, Sagarpura, Surat-395002.
Key Details of the Conference Call
| Detail | Information |
|---|---|
| Event | Earnings Conference Call |
| Period Covered | Q4 and Year ended March 31, 2026 |
| Date of Call | May 25, 2026 |
| Regulation | SEBI LODR Regulation 30(6) |
| File Format | MP3 |
The audio file provides a detailed discussion on the financial outcomes and business operations for the reported periods.
Historical Stock Returns for Zota Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.70% | -5.38% | -11.74% | -26.63% | +13.90% | +663.90% |
What guidance has management provided for revenue growth and margins in FY2027?
How does Zota Health Care plan to navigate potential raw material inflation in the upcoming fiscal year?
Are there any strategic capital expenditures or new product launches expected in the near term?


































